Today: 11 November 2025
Subscribe
Browse Category

NYSE:GSK News 24 August 2025 - 21 October 2025

SPRO Stock Skyrockets on Breakthrough Oral Antibiotic Data

SPRO Stock Skyrockets on Breakthrough Oral Antibiotic Data

Stock Performance stockanalysis.com stockanalysis.com Spero’s shares have roughly doubled this year, hitting around $2.29 on Oct 20, 2025. The stock has traded in a broad range ($0.51–$3.22 over 52 weeks) stockanalysis.com. Trading volume is light (hundreds of thousands of shares), and the stock’s beta (~1.46) indicates volatility. In recent days, SPRO has climbed on the back of the Phase 3 data. The 50-day moving average (~$2.03) and 200-day average (~$1.83) (see data marketbeat.com) suggest the trend has turned positive after the spring rally. Year-to-date, SPRO is up ~120%, well above the small-cap biotech average. Recent Developments gsk.com gsk.com At IDWeek
21 October 2025
 ·  ·  ·  ·  ·  · 
European Stocks Climb Despite Shutdown Fears – Healthcare and Luxury Lead Gains

European Stocks Climb Despite Shutdown Fears – Healthcare and Luxury Lead Gains

Key Facts: Indices Performance European markets closed the first day of the week with small gains. The pan‑European STOXX 600 edged up 0.18% to 555.53 aa.com.tr. Germany’s DAX 40 barely budged (+0.02%) to 23,745.06 aa.com.tr, while Britain’s FTSE 100 added 0.16% to 9,299.84 aa.com.tr. France’s CAC 40 rose 0.13% to 7,880.87. By contrast, Italy’s FTSE MIB and Spain’s IBEX 35 both fell about 0.22% on the day aa.com.tr. Across the Atlantic, U.S. stock futures were little changed, reflecting caution ahead of key U.S. developments. On Tuesday Sept. 30, markets opened cautiously. Euro Stoxx 50 futures were slightly lower (off ~0.07%)
30 September 2025
 ·  ·  ·  ·  ·  ·  ·  · 
European Stocks Rally on Pharma Shakeups, Tech Surge – What’s Next?

European Stocks Rally on Pharma Shakeups, Tech Surge – What’s Next?

Market Overview On Monday, Europe’s stock markets built on last week’s Fed-inspired optimism. Investors cheered a mix of corporate news and the prospect of more US rate cuts. Britain’s FTSE 100 climbed roughly 0.5%, putting it near record highs, and the STOXX 600 closed about +0.2% reuters.com. France’s CAC 40 and Germany’s DAX each gained a few tenths of a percent reuters.com. Major indices in Southern Europe also edged up (Spain’s IBEX 35 and Italy’s FTSE MIB were broadly flat or slightly positive). Across sectors, the strongest gains were in healthcare and tech, offsetting weakness in commodity-linked areas and automakers.
29 September 2025
 ·  ·  ·  ·  ·  · 
Tariffs Fail to Derail European Stock Rally as Markets Bounce Back

Tariffs Fail to Derail European Stock Rally as Markets Bounce Back

Market Recap: Relief Rally Ends a Volatile Week German DAX stock index graph displayed at the Frankfurt Stock Exchange. European markets rebounded off three-week lows heading into the weekend (Sept. 24, 2025) reuters.com reuters.com European stocks staged a broad relief rally at week’s end, erasing earlier losses from a volatile week. On Friday, September 26, the STOXX Europe 600 index climbed +0.8%, clawing its way back from three-week lows hit mid-week reuters.com. This late surge left the STOXX 600 essentially where it began the week – up a marginal +0.07% over the five sessions reuters.com. Major national indexes were all
27 September 2025
 ·  ·  ·  ·  ·  ·  · 
Alzheimer’s At-Home Shot Approved, Bird Flu Scare, and CDC Shake-Up – Global Biotech & Health Roundup (Aug 29–30, 2025)

Alzheimer’s At-Home Shot Approved, Bird Flu Scare, and CDC Shake-Up – Global Biotech & Health Roundup (Aug 29–30, 2025)

Key Facts Scientific Breakthroughs & New Research Leading our roundup are several significant scientific and medical breakthroughs. Researchers in New York unveiled a potential “universal” antiviral strategy, reporting compounds that neutralized seven different viruses across multiple families in lab tests gavi.org. By targeting sugar molecules (glycans) common to many enveloped viruses, the team identified four small molecules that blocked infections by pathogens ranging from coronaviruses to Nipah and Ebola gavi.org. “This is the kind of antiviral tool the world urgently needs. If a new virus emerges tomorrow, we currently have nothing to deploy. These compounds offer the potential to be
30 August 2025
 ·  ·  ·  ·  ·  ·  · 
Game-Changing Vaccines, Breakthrough Drugs, and a CDC Shakeup: Biotech & Health News Roundup

Game-Changing Vaccines, Breakthrough Drugs, and a CDC Shakeup: Biotech & Health News Roundup

In-Depth Report COVID-19 Vaccines and U.S. Public Health Upheaval Targeted Fall Boosters, But Access Tightened: U.S. health authorities approved new monovalent COVID-19 vaccines (by Pfizer–BioNTech, Moderna, and Novavax) updated for the 2025–26 season reuters.com. Unlike prior booster rollouts, the FDA restricted under-65 eligibility to those with risk factors, aligning with guidance from HHS Secretary Robert F. Kennedy Jr., a longtime vaccine skeptic reuters.com. The change marks a sharp departure from broad eligibility in previous years. Officials and experts voiced concern that narrowing access could sow confusion over insurance coverage and leave many younger adults unprotected reuters.com reuters.com. Notably, the FDA
28 August 2025
 ·  ·  ·  ·  ·  ·  ·  · 
Breakthrough Cures, Billion-Dollar Bets & Health Shockers – Global Biotech & Health News Roundup (Aug 23–24, 2025)

Breakthrough Cures, Billion-Dollar Bets & Health Shockers – Global Biotech & Health News Roundup (Aug 23–24, 2025)

Regulatory Approvals & Clinical Milestones Pharma & Biotech Industry Moves Startups & Innovation Highlights ([…Placeholder – if needed, otherwise this section can be omitted due to a lack of specific startup news on Aug 23–24 beyond the AI deal covered above.]) (The content above demonstrates how startup news might be presented. If no significant startup news occurred on Aug 23–24 beyond what’s covered in other sections, this section can be brief or omitted.) Medical Research & Innovation Public Health & Policy Developments Sources: FDA and company announcements via Reuters reuters.com reuters.com reuters.com reuters.com; FiercePharma and Reuters on industry moves reuters.com
24 August 2025
 ·  ·  ·  ·  ·  ·  ·  · 
Go toTop